Registry for Metastatic Lobular Breast Cancer Patients

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Recruiting Observational Study
Metastatic Breast Cancer Lobular Breast Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
150 (estimated)
Sponsor
University of California, San Francisco · Other
Who this trial is looking for

This trial is looking for patients with invasive lobular breast cancer. Participants will provide information that may help create better ways to assess this type of cancer.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with invasive lobular carcinoma.
  • I am at least 18 years old.
  • I can understand and sign a consent form.

You may not be able to join if

  • I have stage I-III breast cancer.
  • I do not have lobular histology on my tumor biopsy.
  • I have another active cancer.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed. 2. Age \>=18 years 3. Any receptor subtype. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Stage I-III breast c…
Contacts

Venezia Garza

415-353-8732

venezia.garza@ucsf.edu

CONTACT